Skip to main content

Advertisement

SpringerLink
Log in

Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the association between vitreomacular adhesion (VMA) and the visual and anatomic outcomes of antivascular endothelial growth factor therapy for macular edema due to branch retinal vein occlusion (BRVO).

Methods

This study included 107 eyes of 107 patients with BRVO who underwent intravitreal injection of 1.25 mg bevacizumab. The presence of VMA was determined with spectral-domain optical coherence tomography (SD-OCT). All eyes underwent best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measurements using SD-OCT immediately before the injection and at 3, 6, 9, and 12 months after the injection. The main outcome measures were changes in BCVA and CRT from baseline.

Results

The VMA(+) and VMA(−) groups consisted of 47 and 60 eyes, respectively, and patients’ age differed significantly between the groups (P < 0.001). In both groups, BCVA and CRT improved after the injection. The VMA(+) group showed better improvement in BCVA than did the VMA(−) group (P = 0.0150), and the presence of VMA was associated with a greater decrease in CRT after adjusting for age (P = 0.0019).

Conclusions

Presence of VMA may be associated with superior visual and anatomic outcome for intravitreal bevacizumab in the treatment of macular edema due to BRVO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol. 1978;22:357–76.

    Article  CAS  PubMed  Google Scholar 

  2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–41.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114:1243–7.

    Article  CAS  PubMed  Google Scholar 

  4. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–82.

    Google Scholar 

  5. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology. 1996;103:551–60.

    Article  CAS  PubMed  Google Scholar 

  6. Kawaji T, Hirata A, Awai N, Takano A, Inomata Y, Fukushima M, et al. Trans-tenon retrobulbar triamcinolone injection for macular edema associated with branch retinal vein occlusion remaining after vitrectomy. Am J Ophthalmol. 2005;140:540–2.

    Article  CAS  PubMed  Google Scholar 

  7. Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol. 2007;143:171–3.

    Article  CAS  PubMed  Google Scholar 

  8. Parodi MB, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophthalmologica. 2009;223:298–305.

    Article  PubMed  Google Scholar 

  9. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419–25.

    Article  PubMed  Google Scholar 

  10. Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141–9.

    Article  PubMed  Google Scholar 

  11. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518–22.

    Article  CAS  PubMed  Google Scholar 

  12. Rouvas A, Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Retina. 2010;30:893–902.

    Article  PubMed  Google Scholar 

  13. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118:1594–602.

    Article  PubMed  Google Scholar 

  14. Campochiaro PA, Heiser JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology. 2010;117:1102–12.

    Article  PubMed  Google Scholar 

  15. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29:511–5.

    Article  PubMed  Google Scholar 

  16. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011;118:101–10.

    Article  PubMed  Google Scholar 

  17. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249:183–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009;29:1242–8.

    Article  PubMed  Google Scholar 

  19. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S, et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration. Am J Ophthalmol. 2007;144:741–6.

    Article  PubMed  Google Scholar 

  20. Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146:218–27.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, Yannuzzi LA, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148:79–82.

    Article  PubMed  Google Scholar 

  22. Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration: an ultrasonic study (in German). Ophthalmologe. 1996;93:660–5.

    Article  CAS  PubMed  Google Scholar 

  23. Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol. 2009;147:621–6.

    Article  PubMed  Google Scholar 

  24. Simpson AR, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Opthalmol. 2012;57:498–509.

    Article  Google Scholar 

  25. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111–8.

    Article  PubMed  Google Scholar 

  26. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411–31.

    Article  CAS  PubMed  Google Scholar 

  27. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137–52.

    Article  PubMed  Google Scholar 

  28. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598–614.

    Article  PubMed  Google Scholar 

  29. Simpson AR, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Ophthalmol. 2012;57:498–509.

    Article  PubMed  Google Scholar 

  30. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009;116:1349–55.

    Article  PubMed  Google Scholar 

  31. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–15.

    Article  CAS  PubMed  Google Scholar 

  32. Nomura Y, Ueta T, Iriyama A, Inoue Y, Obata R, Tamaki Y, et al. Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology. 2012;118:853–9.

    Article  Google Scholar 

  33. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92:1601–5.

    Article  CAS  PubMed  Google Scholar 

  34. Stefánsson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990;31:284–9.

    PubMed  Google Scholar 

  35. Chin H, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556–60.

    Article  PubMed  Google Scholar 

  36. Barton KA, Shui YB, Petrash M, Beebe DC. Comment on: the Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand. 2007;85:339–40.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Tan LE, Orilla W, Hugbes PM, Tsai S, Burke JA, Wilson CG. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci. 2011;52:1111–8.

    Article  CAS  PubMed  Google Scholar 

  38. Kondo M, Ito Y, Terasaki H. Intravitreal bevacizumab (Avastin) for persistent macular edema in vitrectomized eyes: limited effect and early recurrence. Retinal Cases Brief Rep. 2007;1:195–7.

    Article  Google Scholar 

  39. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124–6.

    Article  CAS  PubMed  Google Scholar 

  40. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56:165–74.

    Article  CAS  PubMed  Google Scholar 

  41. Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A. Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol. 2012;56:156–64.

    Article  Google Scholar 

  42. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol. 1999;97:465–9.

    Article  CAS  PubMed  Google Scholar 

  43. Sakuma T, Mizota A, Inoue J, Tanaka M. Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2010;150:876–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

R. Terao, None; K. Yuda, None; K. Kure, None; T. Inoue, None; H. Ohtsu, None; Y. Yanagi, None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Tokyo School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Ryo Terao, Kentaro Yuda, Kayo Kure, Tatsuya Inoue & Yasuo Yanagi

  2. Department of Clinical Trial Data Management, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

    Hiroshi Ohtsu

Authors
  1. Ryo Terao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kentaro Yuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kayo Kure
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Ohtsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Yanagi.

About this article

Cite this article

Terao, R., Yuda, K., Kure, K. et al. Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol 58, 139–145 (2014). https://doi.org/10.1007/s10384-013-0302-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-013-0302-4

Keywords

Search

Navigation